High Dose Chemotherapy and Hematopoietic Progenitor Cell Transplantation for Breast Cancer

Abstract Nowhere has there been more controversy in recent years than in the use of high dose chemotherapy (HDC) with autologous hematopoietic stem cell transplantation for breast cancer, both in the adjuvant setting and for advanced disease. Authors review and comment on the data from the studies so far reported and try to indicate what will be next in this field. They also discuss what may be the attitude to take in our everyday clinical practice, taking into account the availability of new chemotherapeutic agents and targeted therapies.

[1]  G. Hortobagyi.  What is the role of high-dose chemotherapy in the era of targeted therapies? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  E. Thiel,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Stockler,et al.  Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. , 2004, The Lancet. Oncology.

[4]  M. Marangolo,et al.  Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990–1999 , 2003, Bone Marrow Transplantation.

[5]  R. Gray,et al.  Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. , 2003, The New England journal of medicine.

[6]  G. Elfenbein.  Stem-cell transplantation for high-risk breast cancer. , 2003, The New England journal of medicine.

[7]  S. Rodenhuis,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. , 2003, The New England journal of medicine.

[8]  Y. Nieto.  The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. , 2003, Haematologica.

[9]  E. Shpall,et al.  Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Berry,et al.  High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Dancey,et al.  A randomized trial of high-dose chemotherapy (HDCT) with autologous peripheral blood stem cell support (asct) compared to standard chemo therapy (ct) in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) clinical trials group study , 2001 .

[12]  P. Pedrazzoli,et al.  Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. , 2001, Haematologica.

[13]  S. Martino,et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. , 2000, The New England journal of medicine.

[14]  P. Pedrazzoli,et al.  Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Baynes,et al.  High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. , 2000, The oncologist.

[16]  J. Armitage,et al.  Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. , 1999, JAMA.

[17]  R. Vij,et al.  Outcomes of high-dose chemotherapy and autologous stem-cell transplantation in stage IIIB inflammatory breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Gehan,et al.  Survival after autologous hematopoietic stem cell transplantation for patients with inflammatory breast carcinoma , 1999, Cancer.

[19]  E. Shpall,et al.  High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Pater,et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Luini,et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Hortobagyi,et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  N. Schmitz,et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients , 1996, The Lancet.

[24]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[25]  C. Gisselbrecht,et al.  Dose intensive therapy in breast cancer. , 1992, Bone marrow transplantation.

[26]  R. Bast,et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Shea,et al.  High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.